

VIRALEZE™ sales and distribution in Saudi Arabia and GCC

- Starpharma has signed an exclusive sales and distribution agreement for VIRALEZE™ antiviral nasal spray in Saudi Arabia and eight other countries, including the GCC region (United Arab Emirates, Qatar, Kuwait, Oman, and Bahrain)
- VIRALEZE™ is already registered for sale in Saudi Arabia, with launch preparations well advanced. The product registration in Saudi Arabia is expected to facilitate further registrations across the region
- VIRALEZE™ is a broad-spectrum antiviral nasal spray that contains SPL7013, which has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses, including inactivation of >99.9% of the Delta variant of SARS-CoV-2, in laboratory studies that have been published in international, peer reviewed journals

Melbourne, Australia; 3 February 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has signed an exclusive sales and distribution agreement for VIRALEZE™ antiviral nasal spray in Saudi Arabia and eight other countries, including the GCC¹ countries (United Arab Emirates, Qatar, Kuwait, Oman, and Bahrain), with Etqan & Nazahah LLC (E&N). E&N is an agent and distributor of medical and pharmaceutical products, headquartered in Saudi Arabia, that represents international healthcare companies, including Bayer, in the GCC region and other neighbouring countries.

The GCC region is an economic union of Arab states bordering the Gulf, with a population of over 59 million people.

Starpharma will supply VIRALEZE™, with E&N responsible for sales, distribution, and marketing of the product. Under the agreement, VIRALEZE™ will be available to retail consumers, clinics, hospitals, pharmacies, and online. The term of the agreement is 5-years and has performance obligations that include launch requirements and annual minimum purchases.

VIRALEZE™ is registered for sale in Saudi Arabia and this registration, which is the first in the Middle East, is expected to facilitate further registrations across the region. Registration activities in other countries covered by this agreement have already commenced.

Dr Jackie Fairley, Starpharma CEO commented: *"We are very pleased to partner with E&N for the sale and distribution of VIRALEZE™ in Saudi Arabia and the wider GCC region, and to continue building on the brand presence of VIRALEZE™ internationally."*

In addition to this distribution agreement with E&N for the supply of VIRALEZE™ in the initial nine countries in the region, Starpharma and E&N are also negotiating an arrangement for sales and distribution to other neighbouring countries.

VIRALEZE™ is now registered in more than 30 countries, including Europe, Vietnam, India, New Zealand, and Saudi Arabia, and available online in certain markets. VIRALEZE™ is supported by [extensive data and peer-reviewed publications](#), including multiple antiviral studies conducted at The Scripps Research Institute, USA.

¹ Gulf Cooperation Council

About Etqan & Nazahah Company (E&N)

Etqan & Nazahah Company (E&N) is a privately held agent and distributor of medical and pharmaceutical products, headquartered in Saudi Arabia, that represents international healthcare companies in the Gulf Cooperation Council (GCC) region and other neighbouring countries.

E&N's company mission is to improve healthcare for patients and medical professionals in the GCC markets by providing superior products and services, which include ethical pharmaceuticals and OTC products, medical equipment, medical supplies and disposables, including rapid test kits for SARS-CoV-2. E&N represent international companies, including Bayer, where they act as the agent in the region for the sales, distribution, and promotion of healthcare products. E&N is licensed by the Saudi Food and Drug Authority.

VIRALEZE™ Antiviral Nasal Spray

VIRALEZE™ is a broad-spectrum antiviral nasal spray. The antiviral agent in VIRALEZE™, referred to as SPL7013, has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses (including influenza and RSV) and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant, in laboratory studies. VIRALEZE™ is applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus. Importantly, the mechanism of action of VIRALEZE™ means that mutations of the spike protein that make SARS-CoV-2 more infectious, as occurred for the Delta strain, appear to make the virus more susceptible to trapping and blocking by SPL7013.

VIRALEZE™ is registered in more than 30 countries, including Europe, Vietnam, India, New Zealand, and Saudi Arabia, and available in certain markets online. VIRALEZE™ is partnered with LloydsPharmacy in the UK, ADMENTA Italia Group in Italy, HealthCo/TBL in Vietnam, and E&N in countries in the Middle East. VIRALEZE™ is not approved for sale or supply in Australia.

Starpharma acknowledges the \$1 million in funding for the development of VIRALEZE™ provided by the Australian Government's Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a \$22.3 million MRFF initiative that provides up to \$1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered for sale in the Europe, Vietnam, India, Saudi Arabia, and New Zealand, and available outside Australia in certain markets online. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

[Starpharma.com](https://www.starpharma.com) | [Twitter](#) | [LinkedIn](#)

Media: Sumit Media

Grant Titmus

Mob: +61 419 388 161

grant@sumitmedia.com.au**Starpharma Holdings Limited**

Dr Jackie Fairley, Chief Executive Officer

Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

investor.relations@starpharma.com

4-6 Southampton Crescent

Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.